|
|
Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
over 18
|
|
|
|
Other
|
|
|
|
ERLANGEN-ONTAK EU-20246, NCT00056134
|
|
|
Objectives - Compare the efficacy of vaccination with autologous dendritic cells pulsed with tumor and influenza antigen peptides with or without ex vivo CD40-ligand and denileukin diftitox, in terms of tumor-specific T-cell response, in patients with HLA-A1- and/or HLA-A2.1-positive stage III or IV melanoma.
- Determine the safety and tolerability of these vaccinations in these patients.
- Determine tumor response in patients treated with these vaccinations.
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
Biologic therapy - More than 4 weeks since prior systemic immunotherapy
- No concurrent immunotherapy during and for 2 weeks after last vaccination
Chemotherapy - See Disease Characteristics
- More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas [e.g., fotemustine])
- No concurrent chemotherapy during and for 2 weeks after last vaccination
Endocrine therapy - No concurrent corticosteroids during and for 2 weeks after last vaccination
Radiotherapy - No prior radiotherapy to the spleen
- Concurrent palliative radiotherapy allowed for selected metastases (e.g., pain or local complications such as compression)
Surgery - See Disease Characteristics
- Recovered from prior surgery
- No prior splenectomy
- No prior organ allografts
- Concurrent surgery of selected metastases (e.g., pain or local complications such as compression) allowed
Other - No other concurrent investigational drugs during and for 2 weeks after last vaccination
- No concurrent paramedical substance during and for 2 weeks after last vaccination
- No concurrent participation or intent to participate in another clinical trial
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - WBC greater than 2,500/mm3
- Neutrophil count greater than 1,000/mm3
- Lymphocyte count greater than 700/mm3
- Platelet count greater than 75,000/mm3
- Hemoglobin greater than 9 g/dL
- No bleeding disorders
Hepatic - Bilirubin less than 2.0 mg/dL
- No hepatitis B or C
Renal - Creatinine less than 2.5 mg/dL
Cardiovascular - No clinically significant heart disease
Pulmonary - No clinically significant respiratory disease
Immunologic - No active systemic infection
- No immunodeficiency disease
- No evidence of HIV-1, HIV-2, or human T-cell lymphocytic virus-1
- No active autoimmune disease including, but not limited to:
- Lupus erythematosus
- Autoimmune thyroiditis or uveitis
- Multiple sclerosis
- Inflammatory bowel disease
[Note: Vitiligo allowed]
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 4 weeks after study participation
- No organic brain syndrome or significant psychiatric abnormality that would preclude study participation and follow-up
- No contraindication to leukapheresis
- No other active malignant neoplasms
Expected Enrollment 30A total of 8-30 patients will be accrued for this study within 6-12 months. Outcomes Primary Outcome(s)Safety and tolerability as assessed by clinical and laboratory evaluation at every visit Overall survival as assessed by clinical staging (CT scan and positron emission tomography [PET]) every 3 months
Secondary Outcome(s)Depletion of regulatory T-cells as assessed by tetramer stainings at every visit Induction of antigen-specific immune responses as assessed by elispot and tetramer staining at every visit Time to progression as assessed by clinical staging (CT scan and PET) every 3 months Objective response rate as assessed by clinical staging (CT scan and PET) every 3 months
Outline Patients are followed for 10 years.
Trial Contact Information
Trial Lead Organizations Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen | | | Gerold Schuler, Protocol chair | | | | Trial Sites
|
|
|
|
Germany |
|
|
Erlangen |
|
| | | Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen |
| | Gerold Schuler | |
|
Registry Information | | Official Title | | Vaccination of HLA-A1 and/or -A2+ Stage III or IV Melanoma Patients with Tumor Peptide-Loaded Autologous Dendritic Cells with Prior Depletion of CD25-Positive Cells Using Denileukin Difitox (ONTAK) | | Trial Start Date | | 2002-10-25 | | Registered in ClinicalTrials.gov | | NCT00056134 | | Date Submitted to PDQ | | 2003-01-08 | | Information Last Verified | | 2006-08-15 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|